News

The first Phase I study is a double-blind and placebo-controlled single ascending dose study in healthy male volunteers to evaluate the compound’s safety, tolerability, pharmacokinetic profile and pharmacodynamic

The approval is based on data from two Phase III, 12-week, randomized, double-blind, placebo-controlled, multi-center studies as well as a 40 week open label study. In the two

Shionogi has completed the acquisition through a cash tender offer followed by short-form merger of the indirect wholly owned subsidiary of Shionogi with and into Sciele. Sciele is

The placebo-controlled, dose-escalating trial is designed to evaluate the safety, tolerability and intraocular pressure (IOP)-lowering effects of INS117548 in approximately 60 subjects with early stage glaucoma or ocular

Toccata is a 70 patient European multi-center safety study. Constructed to gain the CE Mark for the treatment of atrial arrhythmias, secondary endpoints were designed to evaluate the

The pivotal REACH trial successfully met its primary endpoint by showing that patients treated with MabThera in combination with the current standard chemotherapy were able to significantly extend

Cell-Freeze is used for cryogenic temperature applications as low as -196°C for storage, preservation and transfer. Cell-Freeze containers have a uniquely designed proprietary membrane port with attached cap

The ProFUSE demineralized bone scaffold is a porous, malleable allograft that can be used with Alphatec Spine’s Novel spacers and AlphaGRAFT structural allografts. The ProFUSE product provides a

Analysis of the data indicates that once- daily oral dosing of linaclotide, across a range of doses, significantly reduced abdominal pain and significantly improved constipation symptoms in patients